Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Historical Holders from Q3 2018 to Q3 2025

Symbol
CRNX on Nasdaq
CUSIP
22663K107
Type / Class
Equity / Common Stock
Shares outstanding
94.2M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
108M
Holdings value
$4.49B
% of all portfolios
0.005%
Grand Portfolio weight change
+0%
Number of holders
220
Number of buys
120
Number of sells
-106
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +46% $468M $145M 14M +44.9% FMR LLC Mar 31, 2025
VANGUARD GROUP INC 10% +2% $312M $7.45M 9.31M +2.44% The Vanguard Group Mar 31, 2025
WELLINGTON MANAGEMENT GROUP LLP 8.9% +45% $349M $107M 8.38M +44.3% Wellington Management Group LLP Sep 30, 2025
Farallon Capital Partners, L.P. 6% $165M 5.63M Dapice Joshua J. Aug 29, 2025

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 108M $4.49B +$150M $41.65 220
2025 Q2 105M $3.01B +$75M $28.76 219
2025 Q1 102M $3.42B +$9.85M $33.54 224
2024 Q4 99.7M $5.1B +$758M $51.13 244
2024 Q3 84.5M $4.32B +$33.5M $51.10 232
2024 Q2 82.5M $3.69B +$92.2M $44.79 232
2024 Q1 80.4M $3.76B +$489M $46.81 202
2023 Q4 80.7K $2.87M -$1.39M $35.58 2
2023 Q3 68.5M $2.04B +$443M $29.74 169
2023 Q2 53.9M $971M -$14.3M $18.02 136
2023 Q1 55M $884M +$109K $16.06 126
2022 Q4 54.8M $1B -$29.2M $18.30 118
2022 Q3 51.4M $1.01B +$12.5M $19.64 113
2022 Q2 50.5M $941M +$94M $18.65 106
2022 Q1 45.5M $997M +$24.8M $21.95 111
2021 Q4 44.3M $1.26B +$251M $28.41 112
2021 Q3 33.6M $708M +$17.1M $21.05 91
2021 Q2 32.7M $617M +$43.3M $18.85 81
2021 Q1 30.7M $464M +$5.7M $15.28 77
2020 Q4 30.4M $429M -$4.59M $14.11 84
2020 Q3 30.3M $475M -$19.9M $15.67 70
2020 Q2 31.4M $546M +$189M $17.52 78
2020 Q1 20.7M $304M +$45.4M $14.70 54
2019 Q4 17.5M $440M -$5.48M $25.09 57
2019 Q3 15.2M $229M -$94.2M $15.04 60
2019 Q2 15.3M $383M +$30.9M $25.00 61
2019 Q1 17.7M $403M +$21M $22.76 61
2018 Q4 16.8M $503M +$19.1M $29.99 48
2018 Q3 16.2M $463M +$463M $28.65 48